A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients with HER2 Mutant NSCLC

Trial Identifier: D7811C00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
Start Date: July 2022
Primary Completion Date: September 2023
Study Completion Date: March 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese (China) Translation

Trial Locations

Country Location
CN Baoding, CN, 071000
CN Beijing, CN, 100142
CN Beijing, CN, 100191
CN Changchun, CN, 130000
CN Changsha, CN, 410013
CN Changsha, CN, 410008
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Guangzhou, CN, 510080
CN Guangzhou, CN, 510515
CN Hangzhou, CN, 310022
CN Hangzhou, CN, 310020
CN Harbin, CN, 150081
CN Hefei, CN, 133500
CN Hefei, CN, 230601
CN Linyi, CN, 276000
CN Nanjing, CN, 210029
CN Shandong, CN
CN Shanghai, CN, 200032
CN Shanghai, CN, 200025
CN Shenyang, CN, 110042
CN ShenZhen, CN, 518020
CN Wuhan, CN, 430022
CN Wuhan, CN, 430060
CN Xi’an, CN, 710061
CN Xiamen, CN, 361003
CN Yangzhou, CN, 225001
CN Zhengzhou City, CN, 450000